2026-06-14T03:42:01Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/138762025-06-11T17:04:05Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19611col_20.500.12105_19609

00925njm 22002777a 4500 dc Ta Tang, Thuy-Huong author Luz, Sergio LB author Crainey, James L author Rubio Muñoz, Jose Miguel author 2021-05 Mansonellosis is caused by three filarial parasite species from the genus Mansonella that commonly produce chronic human microfilaraemias: M. ozzardi, M. perstans and M. streptocerca. The disease is widespread in Africa, the Caribbean and South and Central America, and although it is typically asymptomatic it has been associated with mild pathologies including leg-chills, joint-pains, headaches, fevers, and corneal lesions. No robust mansonellosis disease burden estimates have yet been made and the impact the disease has on blood bank stocks and the monitoring of other filarial diseases is not thought to be of sufficient public health importance to justify dedicated disease management interventions. Mansonellosis´s Ceratopogonidae and Simuliidae vectors are not targeted by other control programmes and because of their small size and out-door biting habits are unlikely to be affected by interventions targeting other disease vectors like mosquitoes. The ivermectin and mebendazole-based mass drug administration (iMDA and mMDA) treatment regimens deployed by the WHO´s Elimination of Neglected Tropical Diseases (ESPEN) programme and its forerunners have, however, likely impacted significantly on the mansonellosis disease burden, principally by reducing the transmission of M. streptocerca in Africa. The increasingly popular plan of using iMDA to control malaria could also affect M. ozzardi parasite prevalence and transmission in Latin America in the future. However, a potentially far greater mansonellosis disease burden impact is likely to come from shortcourse curative anti-Wolbachia therapeutics, which are presently being developed for onchocerciasis and lymphatic filariasis treatment. Even if the WHO´s ESPEN programme does not choose to deploy these drugs in MDA interventions, they have the potential to dramatically increase the financial and logistical feasibility of effective mansonellosis management.There is, thus, now a fresh and urgent need to better characterise the disease burden and ecoepidemiology of mansonellosis so that effective management programmes can be designed, advocated for and implemented. Res Rep Trop Med. 2021 May 24;12:93-105. 10.2147/RRTM.S274684 1179-7282 Research and Reports in Tropical Medicine 34079424 http://hdl.handle.net/20.500.12105/13876 Mansonella ozzardi Mansonella perstans Mansonella streptocerca Mansonellosis Wolbachia Doxycycline An Overview of the Management of Mansonellosis